Viewing nowCombinationSitagliptin and Metformin Combination Tablet 50/850 mg
Sitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Daehwa Pharmaceutical Co., Ltd.

MFDS item code 202300758 · Approved 2023.03.06 · Insurance code 645605880
Improvement of glycemic control in patients with type 2 diabetes mellitus
This drug helps control blood sugar levels in patients with type 2 diabetes by using sitagliptin and metformin together. It effectively manages blood sugar when combined with dietary control and exercise therapy, and helps stabilize blood sugar levels. Therefore, it is used to improve blood sugar control in daily life for diabetes patients.
In antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: sitagliptin 100 mg and metformin 2000 mg. This drug is generally taken twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this drug should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients who have not previously received drug therapy for diabetes and whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial dose is 1 tablet of this drug 50/500 mg twice daily. The dose may be increased to 1 tablet of this drug 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see section 2. Contraindications in Precautions for Use). 2. Patients receiving metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this drug may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with concomitant metformin and sulfonylurea, metformin and insulin, or metformin and thiazolidinedione therapy: The initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should take the patient's blood glucose level and current dose into consideration. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this drug is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia caused by the sulfonylurea or insulin (see section 5. General Precautions in Precautions for Use). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this drug. Any change in treatment for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used, with the following dose adjustments, in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis. Treatment should not be initiated with this drug because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see section 2. Contraindications in Precautions for Use).
This drug contains both sitagliptin and metformin and is primarily used for blood sugar control in patients with type 2 diabetes. When taking this drug, severe allergic reactions may occur; therefore, if symptoms such as skin rashes or difficulty breathing arise, discontinue use immediately and consult a physician. Acute pancreatitis has been reported rarely, so if symptoms such as abdominal pain, nausea, or vomiting occur, seek medical attention immediately. The metformin component can cause a rare side effect of severe lactic acidosis, so it is safer for patients with poor kidney function or liver dysfunction to avoid taking this medication. This drug should not be administered to patients with moderately or severely reduced kidney function, acute heart failure, severe infections, or dehydration, and it should be temporarily discontinued before and after surgery. Pregnant or nursing women should avoid taking this drug. During treatment, hypoglycemic symptoms may occur, especially when taken with insulin or sulfonylureas; hence, blood sugar levels should be monitored frequently. Be cautious of the increased risk of hypoglycemia if food intake is irregular, exercise levels suddenly increase, or if certain medications are taken concurrently. This drug contains certain dyes; if you are allergic to any of these components, be sure to consult your physician before taking it. Furthermore, alcohol consumption can increase the risk of lactic acidosis, so excessive drinking should be avoided while taking this medication. Regularly monitor kidney function and blood tests to assess health status, and report any abnormal symptoms to medical personnel immediately. Finally, while taking this medication, a dietary regimen and regular exercise should be maintained to assist in blood sugar control.
Severe allergic reactions, anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, lactic acidosis, hypoglycemia, diarrhea, upper respiratory tract infection, headache, nausea, vomiting, abdominal pain, nasopharyngitis, constipation, arthralgia associated with severe and disability, blistering pemphigoid, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, dyspnea, unstable angina, dizziness, acute renal failure, decreased appetite, itching, weight loss, dermatitis, anorexia
Not everyone experiences these, and they can vary from person to person.
This drug should be stored in a tightly closed container to prevent air or moisture from entering. A storage temperature between 1 degree and 30 degrees Celsius is appropriate. Avoid storing in excessively hot or cold locations.
Pink oval film-coated tablet
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Daehwa Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.